ClinicalTrials.gg
TerminatedNCT04803006Updated Nov 4, 2026Results posted

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

A Phase 2 interventional study of TCD601 in Kidney Transplantation, sponsored by ITB-Med LLC. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by ITB-Med LLC · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision, indication no longer under evaluation
Updated Nov 4, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to understand the study requirements and provide written before any study assessment is performed
  • Male or female patients ≥ 18 to 65 years of age
  • Recipient of a first renal transplant from a non-HLA identical, but at least haploidentical, ABO compatible living donor

Key Exclusion Criteria:

  • Women of , unless willing to comply with the use of highly effective methods of as defined by the protocol
  • A history of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix
  • Recipient with anti-HLA donor-specific antibody (DSA)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Arm 1

    TCD601administered with non-myeloablative conditioning and standard of care immunosuppression

    Biological: TCD601

  • Experimental
    Arm 2

    TCD601administered with non-myeloablative conditioning and standard of care immunosuppression

    Biological: TCD601

Interventions

  • BiologicalTCD601

    Investigational Product

06

What researchers measure

Primary outcomes

  1. The Proportion of Patients Off Immunosuppression With Good Safety and Tolerability

    The proportion of patients off immunosuppression with good safety and tolerability at 24 months assessed by immunosuppression dosing; Serum creatinine (estimated glomerular filtration rate \[eGFR\]); Incidents of Chimeric Transition Syndrome (CTS) and biopsy proven acute rejection (BPAR); Renal biopsy

    Time frame: 24 months

Secondary outcomes

  1. The Incidence of de Novo Donor-specific Antibody

    Time frame: 24 months

  2. The Incidence of Biopsy Proven Acute Rejection, Death and Graft Loss

    Time frame: 24 months

07

Results

Posted Nov 4, 2026
Limitations and caveats
Sponsor decision; early study termination

Participant flow

Study was early terminated and participants were not fully enrolled into Arm 1. No participants were enrolled in Arm 2.

Participant flow — Overall Study
MilestoneArm 1
Started4
Completed0
Not completed4
Withdrew: Sponsor decision; early termination4

Outcome measures

PrimaryThe Proportion of Patients Off Immunosuppression With Good Safety and Tolerability

The proportion of patients off immunosuppression with good safety and tolerability at 24 months assessed by immunosuppression dosing; Serum creatinine (estimated glomerular filtration rate \[eGFR\]); Incidents of Chimeric Transition Syndrome (CTS) and biopsy proven acute rejection (BPAR); Renal biopsy

Time frame:
24 months
Reported as:
Count of participants · Participants
The Proportion of Patients Off Immunosuppression With Good Safety and Tolerability
ParticipantsArm 1
The Proportion of Patients Off Immunosuppression With Good Safety and Tolerability1
SecondaryThe Incidence of de Novo Donor-specific Antibody
Time frame:
24 months
Reported as:
Count of participants · Participants
The Incidence of de Novo Donor-specific Antibody
ParticipantsArm 1
The Incidence of de Novo Donor-specific Antibody3
SecondaryThe Incidence of Biopsy Proven Acute Rejection, Death and Graft Loss
Time frame:
24 months
Reported as:
Count of participants · Participants
The Incidence of Biopsy Proven Acute Rejection, Death and Graft Loss
ParticipantsArm 1
The Incidence of Biopsy Proven Acute Rejection, Death and Graft Loss2

Adverse events

Collected over From enrollment to end of follow up, up to 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 10/4 (0%)2/4 (50%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventArm 1
Engraftment syndromeImmune system disorders2/4
InfluenzaInfections and infestations1/4
PyelonephritisInfections and infestations1/4
Small intestinal obstructionGastrointestinal disorders1/4
Post procedural urine leakInjury, poisoning and procedural complications1/4
Most frequent other events
Most frequent other events
EventArm 1
LeukopeniaBlood and lymphatic system disorders4/4
LymphopeniaBlood and lymphatic system disorders4/4
NeutropeniaBlood and lymphatic system disorders3/4
thrombocytopeniaBlood and lymphatic system disorders3/4
Donor specific antibody presentInvestigations3/4

Baseline characteristics

Study was early terminated and participants were only assigned to Arm 1 (4 doses). No participants were enrolled into Arm 2 (5 doses). No donors were enrolled into the study.

Age, Continuous
Age, Continuous(years)Arm 1
Mean40.0 ± 18.57
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1
Female0
Male4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White1
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1
Hispanic or Latino2
Not Hispanic or Latino2
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Arm 1
United States4
08

Study locations

1 site
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Oct 2025, 33 months.

Results were first posted in Nov 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2021
First posted
Mar 17, 2021
StartActual
Jan 17, 2023
Primary completionActual
Oct 30, 2025
CompletionActual
Oct 30, 2025
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore The optimal regimen for renal allograft tolerance while minimizing chimeric transition syndromeNow The Proportion of Patients Off Immunosuppression With Good Safety and TolerabilityTime frame: 24 months
Nov 4, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedThe incidenceIncidence of biopsy proven acute rejectionBiopsy Proven Acute Rejection, deathDeath and graft lossGraft LossTime frame: 24 months
  • EditedThe incidenceIncidence of de novo donorNovo Donor-specific antibodyAntibodyTime frame: 24 months
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore The optimal regimen for renal allograft tolerance while minimizing chimeric transition syndromeNow The Proportion of Patients Off Immunosuppression With Good Safety and TolerabilityTime frame: 24 months
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedThe incidenceIncidence of biopsy proven acute rejectionBiopsy Proven Acute Rejection, deathDeath and graft lossGraft LossTime frame: 24 months
    • EditedThe incidenceIncidence of de novo donorNovo Donor-specific antibodyAntibodyTime frame: 24 months
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04803006
Lead sponsor
ITB-Med LLC
Responsible party
Sponsor
First posted
Mar 17, 2021
Start date
Jan 17, 2023
Primary completion
Oct 30, 2025
Completion
Oct 30, 2025
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Tracy Killingsworth
study director · Nefro Avillion

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion